亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

ʟ-Histidine Supplementation in Adults and Young Children with Atopic Dermatitis (Eczema)

特应性皮炎 安慰剂 医学 丝状蛋白 组氨酸 病因学 内科学 摄入 胃肠病学 皮肤病科 病理 生物 生物化学 氨基酸 替代医学
作者
Neil K. Gibbs
出处
期刊:Journal of Nutrition [Elsevier BV]
卷期号:150 (Suppl 1): 2576S-2579S 被引量:32
标识
DOI:10.1093/jn/nxaa200
摘要

Atopic dermatitis (AD) is an incurable, inflammatory skin condition that is prevalent (∼20%) in young children. There is an unmet clinical need, particularly in children, for safe interventions that target the etiology of the disease. Deficiencies in the skin barrier protein, filaggrin (FLG) have been identified as major predisposing factors in AD. In mammals, l-histidine is rapidly incorporated into epidermal FLG and subsequent FLG proteolysis releases l-histidine as an important natural moisturizing factor (NMF). It has therefore been hypothesized that l-histidine supplementation would be a safe approach to augment both FLG and the NMF, enhance skin barrier function, and reduce AD severity. In a clinical pilot study, adult subjects (n = 24) with AD took either a placebo or 4 g oral l-histidine daily for 8 wk. Unlike the placebo, l-histidine reduced AD (34% reduction in SCORing Atopic Dermatitis scores; P < 0.003) after 4 wk. Nine and 8 adverse events (AEs), and 1 and 0 severe AEs were recorded in the l-histidine or placebo groups, respectively, with no AE being causally related to l-histidine ingestion. A survey of adults (n = 98) taking 4 g l-histidine daily reiterated a lack of causal AEs and also reported a 33% reduction in topical corticosteroid use. A placebo-controlled, clinical pilot study conducted in young children with AD (n = 49; mean age 3.5 y) taking 0.8 g l-histidine daily, showed that eczema area and severity index scores were reduced by 49% (P < 0.02) at 12 wk, whereas a placebo had no effect. The children taking l-histidine had 50 minor AEs (compared with 39 on placebo), with 78% considered as "not," 18% "unlikely," and 4% "possibly" related to l-histidine ingestion. These studies indicate that at the levels reported, oral l-histidine supplementation is well tolerated and has potential as a safe intervention for long-term use in the management of AD in all age groups.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
无语的幻露完成签到,获得积分10
刚刚
初初初啊发布了新的文献求助10
2秒前
萧雨墨发布了新的文献求助10
3秒前
3秒前
千早爱音完成签到 ,获得积分10
3秒前
DTS发布了新的文献求助10
4秒前
5秒前
5秒前
抚琴祛魅完成签到 ,获得积分10
6秒前
11秒前
何在完成签到,获得积分10
12秒前
Lucas的应助被DTS采纳,获得10
13秒前
15秒前
Ziezer完成签到,获得积分10
16秒前
初初初啊发布了新的文献求助10
16秒前
生性不爱说话完成签到,获得积分10
18秒前
DTS完成签到,获得积分10
20秒前
可爱多婷婷子完成签到 ,获得积分10
20秒前
单身的曲奇完成签到,获得积分10
21秒前
霸气的远望完成签到 ,获得积分10
24秒前
24秒前
Nole的应助被pursuit采纳,获得30
25秒前
迪恩关注了科研通微信公众号
28秒前
初初初啊发布了新的文献求助10
29秒前
reece完成签到 ,获得积分10
31秒前
葡萄味的果茶完成签到 ,获得积分10
33秒前
LeoYiS214完成签到,获得积分10
34秒前
35秒前
37秒前
梨理完成签到 ,获得积分10
38秒前
秀丽战斗机关注了科研通微信公众号
39秒前
39秒前
Nole的应助被科研通管家采纳,获得10
39秒前
39秒前
Hello的应助被科研通管家采纳,获得10
39秒前
39秒前
田様的应助被科研通管家采纳,获得10
39秒前
SciGPT的应助被科研通管家采纳,获得10
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190060
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851884
捐赠科研通 7788155
什么是DOI,文献DOI怎么找? 3436233
关于科研通互助平台的介绍 2559935
邀请新用户注册赠送积分活动 2482792